cd44 polyclonal antibody  (Proteintech)

Journal: Frontiers in Veterinary Science

Article Title: PDGFD maintains ovine tail ADSCs in a proliferative state by suppressing CXCL8 and activating PI3K/MAPK signaling

doi: 10.3389/fvets.2026.1777426

Figure Lengend Snippet: Immunofluorescence identification of CD44 in ovine ADSCs. (a) CD44 immunofluorescence staining (red) shows strong positive expression localized to the cell membrane and cytoplasm. (b) DAPI staining (blue) marks the cell nuclei. (c) Merged image illustrates the subcellular localization of CD44.

Article Snippet: To reduce non-specific binding, cells were blocked with 1% bovine serum albumin (BSA, Bioss, Beijing, China) at room temperature for 30 min. After blocking, cells were incubated overnight at 4 °C with a primary antibody against CD44 (rabbit polyclonal antibody, Bioss, Cat No. bs-55039R, dilution 1:1,000).

Techniques: Immunofluorescence, Staining, Expressing, Membrane

Journal: iScience

Article Title: KRT15 identified by scRNA-Seq and machine learning as stemness regulator and prognostic biomarker in ESCC

doi: 10.1016/j.isci.2026.115020

Figure Lengend Snippet: KRT15 is enriched in ESCC tumor spheroids and positively correlates with the stemness marker CD44 (A) Stem cell enrichment experiments performed in four cell lines, with images captured over time. (B and C) qPCR analysis of CD44 and KRT15 mRNA expression in tumorspheres versus adherent cells from ECA109, KYSE180, KYSE150, and TE1 cell lines. n = 3, statistical analysis performed using an unpaired t test. Data are represented as mean ± SEM. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001. (D) Western blot analysis of CD44 and KRT15 protein expression in tumor spheres compared to adherent cells in ECA109 and KYSE180 cell lines.

Article Snippet: CD44 Polyclonal antibody , Proteintech , Cat#15675-1-AP; RRID: AB_2076198.

Techniques: Marker, Expressing, Western Blot

Journal: iScience

Article Title: KRT15 identified by scRNA-Seq and machine learning as stemness regulator and prognostic biomarker in ESCC

doi: 10.1016/j.isci.2026.115020

Figure Lengend Snippet: KRT15-mediated stemness in ESCC cells is associated with MYC pathway activation and involves upregulation of stemness markers (A) The significantly enriched hallmark pathways identified by GSEA of differentially expressed genes in cluster 0. (B) The GSEA enrichment plot demonstrates a significant enrichment of the MYC_TARGETS_V1 gene set. (C and D) WB results showed that when KRT15 was overexpressed, c-MYC protein levels were synergistically upregulated alongside stemness markers (CD44, SOX2, OCT4); conversely, when KRT15 was knocked down, all these markers exhibited a downward trend.

Article Snippet: CD44 Polyclonal antibody , Proteintech , Cat#15675-1-AP; RRID: AB_2076198.

Techniques: Activation Assay

Journal: Clinical and Experimental Medicine

Article Title: CD44 is associated with papillary thyroid carcinoma metastasis via potential modulation of the immunosuppressive tumor microenvironment

doi: 10.1007/s10238-026-02101-x

Figure Lengend Snippet: Flowchart of this study. A total of 204 patients (82 with nodular goiter (NG) and 122 with papillary thyroid carcinoma (PTC), including 49 with PTC-cervical lymph node metastasis (CLNM) and 73 with PTC-noncervical lymph node metastasis (NCLNM) were analyzed. Proteomic screening was performed on 24 tissue and serum samples (NG = 3, PTC-CLNM = 13, PTC-NCLNM = 8), followed by validation using enzyme-linked immunosorbent assay (ELISA), flow cytometry, and immunohistochemistry (IHC). Bioinformatics analysis, hematoxylin and eosin (H&E) staining, and 3D tissue clearing were conducted to examine CD44 expression and its correlation with IL-10, TGF-β, and Tregs. Statistical analysis included both univariate and multivariate approaches

Article Snippet: After being incubated with 3% H2O2 for 10 min, CD44 polyclonal antibody (Proteintech Cat# 15675-1-AP, RRID: AB_2076198), TGF-β polyclonal antibody (Proteintech Cat# 21898-1-AP, RRID: AB_2811115) and IL-10 monoclonal antibody (Proteintech Cat# 60269-1-Ig, RRID: AB_2881389) was added, and the samples were incubated for 12 h at 4 °C.

Techniques: Biomarker Discovery, Enzyme-linked Immunosorbent Assay, Flow Cytometry, Immunohistochemistry, Staining, Expressing

Journal: Clinical and Experimental Medicine

Article Title: CD44 is associated with papillary thyroid carcinoma metastasis via potential modulation of the immunosuppressive tumor microenvironment

doi: 10.1007/s10238-026-02101-x

Figure Lengend Snippet: CD44 is an independent risk factor for papillary thyroid carcinoma (PTC) metastasis, associated with elevated immunosuppressive cytokines, and organizes the metastatic niche. (A) ( a ), Logistic regression analysis of risk factors for PTC. ( b ), Logistic regression analysis of risk factors for cervical lymph node metastasis (CLNM). (B) Serum levels of CD44, TGF-β, and IL-10 are significantly elevated in PTC patients and further increased in those with CLNM. ( a ), The serum expression levels of CD44 between nodular goiter (NG) and PTC groups. ( b ), The serum expression levels of IL-10 between NG and PTC groups. ( c ), The serum expression levels of TGF-β between NG and PTC groups. ( d ), The serum expression levels of CD44 between PTC-CLNM and PTC with noncervical lymph node metastasis (PTC-NCLNM). ( e ), The serum expression levels of IL-10 between PTC-CLNM and PTC-NCLNM. ( f ), The serum expression levels of TGF-β between PTC-CLNM and PTC-NCLNM. (C) Representative hematoxylin and eosin (H&E) staining of thyroid and lymph node tissues (scale bars: 100 μm). ( a ) Benign thyroid nodule showing regular follicular architecture with uniform epithelial lining and colloid-filled lumens. ( b ) Papillary thyroid carcinoma displaying characteristic features: papillary fronds with fibrovascular cores, nuclear enlargement, overlapping, and longitudinal nuclear grooves. ( c ) Non-metastatic lymph node with preserved architecture including germinal centers and sinuses. ( d ) Metastatic lymph node from PTC patient, showing replacement of normal lymphoid tissue by tumor nests and intralymphatic tumor emboli. D. 3D tissue clearing images of the PTC microenvironment, obtained by confocal microscopy, reveal key spatial interactions. ( a ), Merged multichannel image with a composite view of the integrated landscape of the nuclei (DAPI, blue), CD44 + tumor cells (green), and CD25 + regulatory T cells (Tregs, red) followed by ( b ) CD44 + tumor cells (green) with highlighting of stemness-associated metastatic morphology and ( c ) DAPI-stained nuclei (blue) as an architectural context of cellular distribution; ( d ), CD25⁺ Tregs (red) illustrating immunosuppressive niche formation.(* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, NS P > 0.05)

Article Snippet: After being incubated with 3% H2O2 for 10 min, CD44 polyclonal antibody (Proteintech Cat# 15675-1-AP, RRID: AB_2076198), TGF-β polyclonal antibody (Proteintech Cat# 21898-1-AP, RRID: AB_2811115) and IL-10 monoclonal antibody (Proteintech Cat# 60269-1-Ig, RRID: AB_2881389) was added, and the samples were incubated for 12 h at 4 °C.

Techniques: Expressing, Staining, Confocal Microscopy

Journal: Clinical and Experimental Medicine

Article Title: CD44 is associated with papillary thyroid carcinoma metastasis via potential modulation of the immunosuppressive tumor microenvironment

doi: 10.1007/s10238-026-02101-x

Figure Lengend Snippet: CD44 promotes an immunosuppressive microenvironment and drives tumor cell proliferation in PTC (A) Immunohistochemical analysis reveals upregulated CD44, IL-10, and TGF-β protein expression in PTC tissues, particularly with lymph node metastasis. ( a - c ), The negative control of PBS instead of first antibody. ( d - f ), The immunohistochemical results of CD44, IL-10 and TGF-β expression in the thyroid nodule tissue of patients in the nodular goiter (NG) group. ( g - i ), The immunohistochemical results of CD44, IL-10 and TGF-β expression in the thyroid nodule tissue of patients in the papillary thyroid carcinoma with noncervical lymph node metastasis (PTC-NCLNM) group. ( j - l ), The immunohistochemical results of CD44, IL-10 and TGF-β expression in the thyroid nodule tissue of patients in the PTC with cervical lymph node metastasis (PTC-CLNM) group. (B) Flow cytometry demonstrates increased circulating Treg frequency in PTC patients, which escalates with metastatic progression. ( a - c ), The proportion of Treg cells among CD4 + T cells in the blood of patients from the NG, PTC-NCLNM, and PTC-CLNM groups. ( d ) The quantitative comparison of Treg cell proportions in the blood between NG and PTC patients. ( e ) The quantitative comparison of Treg cell proportions in the blood between PTC-NCLNM and PTC-CLNM patients. (C) Genetic manipulation of CD44 confirms its direct role in enhancing PTC cell proliferation in vitro. Comparison of cell viability among TPC-1-CD44-KD, TPC-1-CD44-KD empty vector control (TPC-1-EV), and CD44 overexpression (TPC-1-CD44-OE) groups. (* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001)

Article Snippet: After being incubated with 3% H2O2 for 10 min, CD44 polyclonal antibody (Proteintech Cat# 15675-1-AP, RRID: AB_2076198), TGF-β polyclonal antibody (Proteintech Cat# 21898-1-AP, RRID: AB_2811115) and IL-10 monoclonal antibody (Proteintech Cat# 60269-1-Ig, RRID: AB_2881389) was added, and the samples were incubated for 12 h at 4 °C.

Techniques: Immunohistochemical staining, Expressing, Negative Control, Flow Cytometry, Comparison, In Vitro, Plasmid Preparation, Control, Over Expression

Journal: Journal of Nanobiotechnology

Article Title: Low-dose X-ray-activated radiodynamic therapy via a lutetium-coordinated nanoplatform synergizing PARP inhibition and ferroptosis

doi: 10.1186/s12951-026-04027-8

Figure Lengend Snippet: Physicochemical characterization, stability, and drug release profile of BPNS@Lu 3+ /Lap-CMV. (a) Hydrodynamic size distribution of BPNS@Lu 3+ /Lap-CMV. (b) Zeta potential of BPNS, BPNS@Lu 3+ , BPNS@Lu 3+ /Lap, CMV, and BPNS@Lu 3+ /Lap-CMV ( n = 3). (c) UV–vis absorption spectra of Lap, BPNS/Lap, BPNS@Lu 3+ /Lap-CMV and BPNS. (d) Raman scattering spectra of BPNS, BPNS@Lu 3+ /Lap, BPNS@Lu 3+ /Lap-CMV. (e) Full-survey XPS spectrum and (f) high-resolution Lu 4 d XPS spectrum of BPNS@Lu 3+ /Lap-CMV. (g) Western blot analysis of the membrane marker CD44 and the nuclear protein histone H1t in (1) 4T1 cells, (2) CMs, (3) CMV, (4) BPNS@Lu 3+ /Lap, and (5) BPNS@Lu 3+ /Lap-CMV. (h) Protein concentration of CMV and BPNS@Lu 3+ /Lap-CMV by BCA assay. (i) CLSM images of cellular uptake of BPNS@Lu 3+ /Lap-CMV. Cy5 (red) represents the BPNS@Lu 3+ /Lap core, DiO (green) represents the tumor membrane shell, and DAPI (blue) stains the cell nuclei. (j) TEM images and elemental mapping images of BPNS, BPNS@Lu 3+ , BPNS@Lu 3+ /Lap, and BPNS@Lu 3+ /Lap-CMV (scale bar = 200 nm). (k) Colloidal stability of bare BPNS and (l) BPNS@Lu 3+ /Lap in aqueous solution over a 9-day period. (m) Cumulative release profiles of Lu 3+ and (n) Lap from BPNS@Lu 3+ /Lap-CMV under physiological (pH 7.4), acidic (pH6.0, pH 4.8), and chelating (with EDTA) conditions over 96 h (n = 3). Data are presented as mean ± standard deviation

Article Snippet: Rabbit anti-H1t antibody (catalog No. bs-1413R), and Rabbit anti-CD44 antibody (catalog No. bs-4916R) were purchased from Bioss (Beijing, China).

Techniques: Zeta Potential Analyzer, Western Blot, Membrane, Marker, Protein Concentration, BIA-KA, Standard Deviation